Page last updated: 2024-11-12
azd2066
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16041426 |
| CHEMBL ID | 3545164 |
| SCHEMBL ID | 1848325 |
| MeSH ID | M0593468 |
Synonyms (20)
| Synonym |
|---|
| mq908y1zb2 , |
| 934282-55-0 |
| azd-2066 |
| unii-mq908y1zb2 |
| pyridine, 4-(5-((1r)-1-(5-(3-chlorophenyl)-3-isoxazolyl)ethoxy)-4-methyl-4h-1,2,4-triazol-3-yl)- |
| azd2066 |
| azd 2066 [who-dd] |
| 4-(5-{(1r)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4h-1,2,4-triazol-3-yl)pyridine |
| SXWHYTICXCLKDG-GFCCVEGCSA-N , |
| SCHEMBL1848325 |
| azd 2066 |
| CHEMBL3545164 |
| 5-(3-chlorophenyl)-3-[(1r)-1-[[4-methyl-5-(4-pyridyl)-1,2,4-triazol-3-yl]oxy]ethyl]isoxazole |
| 4-[5-[(1r)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine |
| AKOS027470229 |
| DB12644 |
| HY-110255 |
| CS-0033120 |
| Q27284176 |
| 5-(3-chlorophenyl)-3-[(1r)-1-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)oxy]ethyl]-1,2-oxazole |
Research Excerpts
Overview
AZD2066 is a new chemical entity pharmacologically characterized as a selective, negative allosteric modulator of the metabotropic glutamate receptor subtype 5.
| Excerpt | Reference | Relevance |
|---|---|---|
| "AZD2066 is a new chemical entity pharmacologically characterized as a selective, negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). " | ( A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - estimating occupancy in the absence of a reference region. Cselényi, Z; Halldin, C; Hooker, AC; Kågedal, M; Karlsson, MO; Nyberg, S; Raboisson, P; Ståhle, L; Stenkrona, P; Varnäs, K, 2013) | 2.05 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The pharmacokinetic parameters for the probe drugs and their metabolites in plasma and urinary recovery were determined." | ( Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. Andersson, A; Baranczewski, P; Nordmark, A; Ståhle, L; Wanag, E, 2014) | 0.67 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.84
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.84) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (50.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 2 (33.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||